22000
employees
140
Close to 140 countries where the Group’s
medicines are distributed
20%
Close to 20% of revenue from brand-name
medicines invested in R&D each year
€ 5.9 billion
5.9 euros in revenue in 2023-2024 including
€4.5 billion for brand-name medicines and
€1.4 billion for generic activities
3 therapeutic areas
Oncology, Cardiometabolism & venous diseases,
Neurology